Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Inclusion Criteria: 1. Hormone receptor positive; 2. previously untreated patients who do not receive hormonal therapy, or initial endocrine treatment failure or first -line endocrine treatment of relapse and metastasis failure; 3. patients who do not receive hormonal therapy must be histologically confirmed invasive ductal carcinoma, can be surgery, but must be satisfied one of the following: (1) elderly (≥70 years), or with severe heart or other systemic complications, belonging to high risk of general anesthesia, (2) have will of conserving the breast,but larger tumors (≥3cm) not suitable for breast-conserving surgery. 4. patients with metastatic breast cancer must have evaluable lesions 5. normal laboratory values: 6. informed consent (ethical approval document No. :1112105-1); 7. life expectancy of at least 3 months; 8. Postmenopausal or premenopausal with bilateral oophorectomy. Exclusion Criteria: 1. have had radiotherapy or other local treatment for measurable lesions before the start of study received within 3 months 2. organ transplant (except for autologous or allogeneic bone marrow transplantation); 3. have evidences of central nerve system metastases or have a history of mental illness that uncontrol; 4. unable to swallow tablets, or malabsorption patients, or patients with poor upper gastrointestinal integrity; 5. unwilling or unable to comply with study protocol or unable to meet the follow up; 6. patients who researchers considered were not suitable to participate.